Simeprevir restores the anti-Staphylococcus activity of polymyxins

Simeprevir restores the anti-Staphylococcus activity of polymyxins

Abstract Methicillin-resistant Staphylococcus aureus (MRSA) infection poses a severe threat to global public health due to its high mortality. Currently, polymyxins are mainly used for the treatment of Gram-negative bacterial-related infection, while exhibiting limited antibacterial activities again...

Full description

Bibliographic Details
Main Authors:	Yuan Wu, Pingyun Wu, Ruolan Wu, Huilong Li, Yao Duan, Chaoni Cai, Zixin Liu, Pengfei She, Di Zhang
Format:	Article
Language:	English
Published:	SpringerOpen 2023-11-01
Series:	AMB Express
Subjects:	Staphylococcus aureus Simeprevir Polymyxins Antimicrobial Drug repurposing Persister cells
Online Access:	https://doi.org/10.1186/s13568-023-01634-8

Similar Items

Transcriptomic Analysis of the Activity of a Novel Polymyxin against <named-content content-type="genus-species">Staphylococcus aureus</named-content>
by: Jinxin Zhao, et al.
Published: (2016-08-01)

Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption
by: Shasha Liu, et al.
Published: (2022-11-01)

Polymyxin B and ethylenediaminetetraacetic acid act synergistically against Pseudomonas aeruginosa and Staphylococcus aureus
by: Samuel J. M. Hale, et al.
Published: (2024-02-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations
by: Augustine Koh Jing Jie, et al.
Published: (2022-11-01)

Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus
by: Yaqian Liu, et al.
Published: (2021-08-01)

Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement
by: Rafael Mahieu, et al.
Published: (2015-11-01)

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens
by: Thien B. Tran, et al.
Published: (2018-04-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Repurposing of the antimalarial agent tafenoquine to combat MRSA
by: Pengfei She, et al.
Published: (2023-12-01)

Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C
by: É Z Burnevich
Published: (2014-11-01)

Challenges in the Detection of Polymyxin Resistance: From Today to the Future
by: Rebeca Siqueira Rubens, et al.
Published: (2024-01-01)

Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus
by: Pengfei She, et al.
Published: (2022-01-01)

In vitro polymyxin activity against clinical multidrug-resistant fungi
by: Hanane Yousfi, et al.
Published: (2019-04-01)

Drug repurposing: insights into the antimicrobial effects of AKBA against MRSA
by: Yingjia Li, et al.
Published: (2024-01-01)

Progress in the study of polymyxin resistance and its mechanism
by: CAI Jia’an, et al.
Published: (2022-03-01)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
by: Leen Vijgen, et al.
Published: (2017-05-01)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
by: Anne Laurain, et al.
Published: (2019-04-01)

Interruption of the tricarboxylic acid cycle in Staphylococcus aureus leads to increased tolerance to innate immunity
by: Alexis M. Hobbs, et al.
Published: (2021-12-01)

Review of the international consensus guidelines for the optimal use of the polymyxins
by: Eliseeva E.V., et al.
Published: (2019-12-01)

Generation of Persister Cells of Pseudomonas aeruginosa and Staphylococcus aureus by Chemical Treatment and Evaluation of Their Susceptibility to Membrane-Targeting Agents
by: Lucia Grassi, et al.
Published: (2017-10-01)

Antimicrobial Stewardship and Its Impact on the Changing Epidemiology of Polymyxin Use in a South Indian Healthcare Setting
by: Dipu T. Sathyapalan, et al.
Published: (2021-04-01)

Genetic Screen Reveals the Role of Purine Metabolism in Staphylococcus aureus Persistence to Rifampicin
by: Rebecca Yee, et al.
Published: (2015-12-01)

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation
by: Dongna Zou, et al.
Published: (2021-04-01)

Novel Cecropin-4 Derived Peptides against Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Jian Peng, et al.
Published: (2021-01-01)

Antimicrobial Stewardship Programs: A Review of Strategies to Avoid Polymyxins and Carbapenems Misuse in Low Middle-Income Countries
by: Fabrício Rodrigues Torres de Carvalho, et al.
Published: (2022-03-01)

Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice
by: O O Znoyko, et al.
Published: (2016-11-01)

Staphylococcus argenteus from rabbits in Thailand
by: Nitaya Indrawattana, et al.
Published: (2019-04-01)

Discerning the role of polymyxin B nonapeptide in restoring the antibacterial activity of azithromycin against antibiotic-resistant Escherichia coli
by: Farah Al-Marzooq, et al.
Published: (2022-09-01)

Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired <i>Staphylococcus aureus</i> Infections
by: Veronica Folliero, et al.
Published: (2023-09-01)

Polymyxin B sulphate
by: 982 SIRIM

Eradication of <i>Staphylococcus aureus</i> Biofilm Infection by Persister Drug Combination
by: Rebecca Yee, et al.
Published: (2022-09-01)

Genome-guided purification and characterization of polymyxin A1 from Paenibacillus thiaminolyticus SY20: A rarely explored member of polymyxins
by: Ya-ping Wu, et al.
Published: (2022-11-01)

Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters
by: Sun Ju Kim, et al.
Published: (2024-04-01)

Complete genome and plasmid sequences of Staphylococcus aureus strain COL52-A5 isolated from a persistent nasal carrier
by: Oscar Montes, et al.
Published: (2022-03-01)

Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study
by: Zhenping Wu, et al.
Published: (2023-08-01)

Polymyxin Delivery Systems: Recent Advances and Challenges
by: Natallia V. Dubashynskaya, et al.
Published: (2020-04-01)

<i>Staphylococcus aureus</i> Adaptation to the Skin in Health and Persistent/Recurrent Infections
by: Ana-Katharina E. Gehrke, et al.
Published: (2023-10-01)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
by: Amar Deep Sharma, et al.
Published: (2023-02-01)